John Walker, MD
Family Medicine · The Woodlands, TXNPI 1114959301
Payments from drug & device makers
Across 220 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$953
- Lilly USA, LLC$483
- AbbVie$285
- AstraZeneca$241
- Pfizer$226
- Boehringer Ingelheim$191
- plus $1K from 32 others
What the payments were for
- Food & beverage$3,768100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 67 | $953 |
| Lilly USA, LLC | 30 | $483 |
| AbbVie(2 entities) | 15 | $285 |
| AstraZeneca | 14 | $241 |
| Pfizer | 11 | $226 |
| Boehringer Ingelheim | 11 | $191 |
| Abbott | 9 | $186 |
| GSK | 9 | $147 |
| Seqirus USA Inc | 6 | $120 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $86 |
| Amgen | 5 | $85 |
| Radius Health, Inc. | 4 | $79 |
| Sanofi Pasteur Inc. | 3 | $78 |
| Hologic Sales And Service, LLC | 2 | $59 |
| Lucid Diagnostics Inc. | 2 | $53 |
| Noven Therapeutics, LLC | 3 | $48 |
| Eisai Inc. | 2 | $41 |
| Merck | 2 | $30 |
| Dexcom, Inc. | 1 | $27 |
| Corium, LLC | 1 | $27 |
| Medline Industries LP | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Bayer | 1 | $20 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| IBSA Pharma Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $18 |
| Exact Sciences | 1 | $18 |
| Neos Therapeutics, LP | 1 | $17 |
| Dynavax Technologies Corporation | 1 | $16 |
| Tolmar, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $16 |
| Cranial Technologies, Inc | 1 | $15 |
| Medtronic | 1 | $13 |
| Dermira, Inc. | 1 | $12 |
How this compares
$3,768 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $168,942 |
| JardianceEmpagliflozin | 39 | $56,807 |
| MounjaroTirzepatide | 35 | $40,392 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 175 | $38,756 |
| TrulicityDulaglutide | 19 | $33,388 |
| RybelsusSemaglutide | 20 | $28,902 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 81 | $26,405 |
| FarxigaDapagliflozin Propanediol | 14 | $16,234 |
| JanuviaSitagliptin Phosphate | 14 | $15,266 |
| EliquisApixaban | 11 | $15,164 |
| Spiriva HandihalerTiotropium Bromide | 19 | $13,596 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $11,066 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $7,108 |
| Atorvastatin Calcium | 729 | $6,442 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 20 | $6,151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $953 | $197,844127 claims |
| Lilly USA, LLCMounjaro, Trulicity | $483 | $73,78054 claims |
| Boehringer IngelheimJardiance | $191 | $56,80739 claims |
| GSKShingrix, Arexvy, Anoro Ellipta | $147 | $50,042206 claims |
| PfizerAbrysvo, Eliquis | $226 | $41,56992 claims |
| AstraZenecaFarxiga | $241 | $16,23414 claims |
| MerckJanuvia | $30 | $15,26614 claims |
| AbbVieSynthroid | $285 | $3,27044 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in The Woodlands
- Scott KahneyThe Woodlands$8M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.